Novo Nordisk A/S Files Annual Report with the SEC

PRINCETON, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Novo Nordisk A/S has filed its Annual Report 2007 on Form 20-F for the financial year 2007 with the US Securities and Exchange Commission (SEC), incorporating by reference the Novo Nordisk A/S Annual Report 2007. The reports are available at the SEC's website, www.sec.gov, as well as at novonordisk.com under the "Investors" section.

Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form at novonordisk.com/investors/download-centre or upon request to either telephone number (609) 712-8127 or by e-mail to cqfr@novonordisk.com. When e-mailing, please state the exact mailing address and the document(s) you wish to receive.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.



CONTACT: Media: Outside North America: Mike Rulis, +45-4442-3573,
mike@novonordisk.com, or In North America: Sean Clements, +1-609-514-8316,
secl@novonordisk.com, or Investors: Outside North America: Mads Veggerby
Lausten, +45-4442-7945, mlau@novonordisk.com, or Hans Rommer,
+45-4442-4765, hrmm@novonordisk.com, or In North America: Christian Qvist
Frandsen, +1-609-919-7937, cqfr@novonordisk.com, all of Novo Nordisk

Web site: http://novonordisk.com/
http://novonordisk-us.com/

Back to news